108
Participants
Start Date
March 4, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Envafolimab+Lenvatinib
"Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle."
Envafolimab
Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
RECRUITING
Chongqing University Three Gorges Hospital, Chongqing
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
The Second Xiangya Hospital of Central South University, Changsha
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
:Nanjing Maternity and Child Health Care Hospital, Nanjing
RECRUITING
Qilu Hospital of Shandong University, Jinan
RECRUITING
Shandong Cancer Hospital, Jinan
RECRUITING
Tai'an Center Hospital, Tai’an
RECRUITING
:Linyi Cancer Hospital, Linyi
RECRUITING
Tianjin Medical University Cancer Institute&Hospital, Tianjing
RECRUITING
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou
RECRUITING
Ganzhou Cancer Hospital, Ganzhou
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Yueyang Center Hospital, Yueyang
RECRUITING
Wuhan Union Hospital of China, Wuhan
RECRUITING
:Hubei Cancer Hospital, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Sun Yat-Sen Memorial Hospital, Guangzhou
3D Medicines (Sichuan) Co., Ltd.
INDUSTRY